Skip to main content
Premium Trial:

Request an Annual Quote

DeCode, Pharmacia Enter Cardiology Research Collaboration

NEW YORK, Jan. 15 - DeCode genetics has launched a pharmacogenomics alliance with Pharmacia in order to probe the genetics of heart disease progression, the company said on Tuesday.

 

The companies hope to isolate genetic markers that can be used to identify patients who will benefit from the cardiovascular drugs that Pharmacia is currently developing. Specifically, under terms of the deal, deCode will use its population data and genetic marker-discovery techniques to identify patients who are predisposed to progress rapidly from early-stage to advanced heart disease.

 

Terms of the deal further call for the Icelandic population genetics company will receive contract fees through Encode, its pharmacogenomics, and CRO subsidiary. Encode may also receive royalties on diagnostic tests or cardiovascular drug sales, if Pharmacia exercises license options.

 

Further financial details were not disclosed.

 

The therapeutic goal of the partnership is to make it possible early on to identify patients who are likely to develop advanced heart disease, and provide preventive treatment, deCode CEO Kari Stefansson said in a statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.